Rinat Rotem‐Yehudar

The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti–PD-1 antibody

Don M. Benson, Courtney E. Bakan, Anjali Mishra et al. · Blood · 2010 · 797 citations · Full text

Phase I Safety and Pharmacokinetic Study of CT-011, a Humanized Antibody Interacting with PD-1, in Patients with Advanced Hematologic Malignancies

Raanan Berger, Rinat Rotem‐Yehudar, Gideon Slama et al. · Clinical Cancer Research · 2008 · 692 citations

PD-1–Expressing Tumor-Infiltrating T Cells Are a Favorable Prognostic Biomarker in HPV-Associated Head and Neck Cancer

Cécile Badoual, Stéphane Hans, Nathalie Merillon et al. · Cancer Research · 2012 · 623 citations

Neck Cancer, Hpv-associated Head, T-regulatory Cell +21

Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial

Jason R. Westin, Fuliang Chu, Min Zhang et al. · The Lancet Oncology · 2013 · 528 citations · Full text

Lymphoid Neoplasia, Medicine, Immunology +10

Disabling Immune Tolerance by Programmed Death-1 Blockade With Pidilizumab After Autologous Hematopoietic Stem-Cell Transplantation for Diffuse Large B-Cell Lymphoma: Results of an International Phase II Trial

Philippe Armand, Arnon Nagler, Edie Weller et al. · Journal of Clinical Oncology · 2013 · 437 citations · Full text